Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin and Renal Endothelial Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female and male patients aged between 18 and 75 years~* fasting LDL C concentrations \>=160 and \< 250mg/dl~* fasting TG concentrations =\< 350mg/dl~Exclusion Criteria:~* History of statin induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins).~* History of hypersensitivity reaction to inulin.~* Lipid-lowering drugs (including lipid lowering dietary supplements of food additives) within the last 4 weeks.~* Diabetes mellitus, defined as glycosylated hemoglobin (HbA1C) above the upper limit of normal (ULN).~* Uncontrolled arterial hypertension (\>160/100mm Hg).~* Subjects considered to be unstable (event within 12 weeks) by the investigator after the following events: a myocardial infarction, unstable angina, myocardial revascularisation (PTCA, CABG surgery or another revascularisation procedure) or a transient ischaemic attack (TIA) or stroke.~* Significant arrythmias or conduction disturbances.~* Congestive heart failure (NYHA classes III or IV).~* Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception or have positive serum pregnancy test (a serum beta-human chorionic gonadotropin analysis).~* History of homozygous familial hypercholesterolaemia or known type III hyperlipoproteinemia (familial dysbetalipoproteinemia).~* Use of concomitant medications.~* Current active liver disease(SGPT \> 2xULN) or severe hepatic impairment.~* Unexplained serum CK \> 3 times ULN (e.g. not due to recent trauma, intramuscular injections, heavy exercise etc.).~* Serum creatinine \> 2,0 mg/dl and creatinine clearance \<80ml/min.~* History of nephrolithiasis with calcium oxalate aggregation.~* Uncontrolled hypothyroidism defined as a thyroid stimulating hormone (TSH) \> 1,5 times the UL or subjects whose thyroid replacement therapy was initiated within the last 3 month.~* Severe disorders of the gastrointestinal tract or other diseases which interfere with the pharmacodynamics and pharmacokinetics of the study drug.~* History of malignancy(unless a documented disease-free period exceeding 10 years is present) with the exception of basal cell or squamous cell carcinoma of the skin. Women with a history of cervical dysplasia would be permitted to enter the study provided they have 3 consecutive clear Papanicolaou (Pap) smears.~* History of organ allografts.~* Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subjects´s safety or successful participation in the trial.~* Participation in a clinical study within 4 weeks preceding treatment start.~* Past or present alcohol or drug abuse.~* Suspected or confirmed poor compliance.~* Previous enrolment in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).